JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works

This time last year, the life science world descended into San Francisco for the 2020 J. P. Morgan healthcare conference, doing the normal things like blowing a whole year’s budget in one day for a hotel room, shaking hands, doing deals and, if you’re like us, asking questions.

In the background, and it seemed at the time quite far in the background, was a strange new respiratory disease coming out of an area in China that looked alarming but appeared to be under control.